Kodiak Q3 Loss Widens to $66.2M; $69M ATM Raise Extends Runway Into 2027
KOD has more than doubled off its 52-week low of $18.05 on light trading volume (0.2× avg).
Summary
Kodiak reported a $66.2 million Q3 net loss and $88.7 million in cash, then added $69 million in post-quarter ATM proceeds that management says funds operations into 2027. Zenkuda's BLA is planned for Q4 2026 and KSI-101 PEAK topline data are due in December 2026.
Key Events · Earnings and Guidance · KOD
-
Q3 Net Loss Widens to $66.2M
Net loss was $66.2 million, or $1.05 per share, versus $61.5 million, or $1.16 per share, a year earlier. R&D rose to $58.3 million from $50.5 million on higher PEAK/PINNACLE and ALTO clinical activity.
-
$69M ATM Raise Extends Runway
Kodiak raised $69 million in net proceeds from common stock sales under its ATM after September 30. With $88.7 million of cash at quarter-end, management expects funding to support operations into 2027.
-
Going-Concern Language Eased
The release says current cash will support operations into 2027, a shift from the going-concern doubt previously disclosed in the Q2 2026 10-Q. The forward-looking statements still flag that risk.
-
Zenkuda BLA Planned for Q4 2026
A three-indication BLA covering wet AMD, diabetic retinopathy and retinal vein occlusion is planned for the fourth quarter of 2026, backed by five positive Phase 3 studies.
Analysis · KOD · Life Sciences
This is the first hard look at Kodiak's finances since the September DAYBREAK win sent the stock from roughly $38 to above $100. The quarter itself was a cash burn story: a $66.2 million net loss and R&D up to $58.3 million as the PEAK/PINNACLE and ALTO trials scale. What changes the picture is the $69 million raised through the ATM after quarter-end, which lifts cash from $88.7 million and lets management say it expects funding into 2027 — a meaningful step back from the going-concern doubt previously disclosed in the Q2 10-Q. Against that, the equity is being sold into strength, and the next binary events are close: Zenkuda's multi-indication BLA is planned for Q4 2026 and KSI-101 PEAK topline is due in December 2026. A miss on either would hit a stock already trading near its 52-week high.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KOD was trading at $108.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8B. The 52-week trading range was $18.05 to $112.31. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.